Export

ATC codes: J01CF02
EMLc
Indication
Bacterial cellulitis, erysipelas or lymphangitis ICD11 code: 1C00
INN
Cloxacillin
Medicine type
Chemical agent
Antibiotic groups
List type
Core (EML)
(EMLc)
Additional notes
*cloxacillin, dicloxacillin and flucloxacillin are preferred for oral administration due to better bioavailability
Formulations
Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid ; 250 mg per 5 mL (as sodium salt) powder for oral liquid (EMLc)
Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection ; 250 mg in vial (as sodium salt) powder for injection (EMLc)
Oral > Solid > capsule: 500 mg (as sodium salt) ; 1 g (as sodium salt) ; 250 mg (as sodium salt) (EMLc)
EML status history
First added in 2017 (TRS 1006)
Changed in 2021 (TRS 1035)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
Medicines within the same pharmacological class can be used
Therapeutic alternatives limitations
Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup: J01CF Beta-lactamase resistant penicillins.
Therapeutic alternatives limitations for EMLc
Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup: J01CF Beta-lactamase resistant penicillins.
Patent information
Patents have expired in most jurisdictions
Wikipedia
DrugBank
Expert Committee recommendation
The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc. - the addition of new formulations of cefalexin (dispersible tablet 125 mg and 250 mg) to the EMLc. - the addition of new strength formulations of cloxacillin (capsule 250 mg, powder for injection 250 mg (as sodium) and powder for oral liquid 250 mg/5 mL (as sodium) on the EMLc.
EML recommendations: Bacterial cellulitis, erysipelas or lymphangitis
First choice
Second choice